CR20170496A - Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas - Google Patents

Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas

Info

Publication number
CR20170496A
CR20170496A CR20170496A CR20170496A CR20170496A CR 20170496 A CR20170496 A CR 20170496A CR 20170496 A CR20170496 A CR 20170496A CR 20170496 A CR20170496 A CR 20170496A CR 20170496 A CR20170496 A CR 20170496A
Authority
CR
Costa Rica
Prior art keywords
vivic
sulfonimidoilpurinone
profilaxis
infections
derivatives
Prior art date
Application number
CR20170496A
Other languages
English (en)
Inventor
Kun; Miao
Chungen Liang
Hongying; Yun
Xiufang; Zheng
Jianping Wang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20170496A publication Critical patent/CR20170496A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente invención se refiere a compuestos de fórmula (I), en la que R1, R2 y R3 son como se han descrito en el presente documento, y sus profármacos o sales, enantiómeros o diastereómeros farmacéuticamente aceptables de los mismos, y composiciones que incluyen los compuestos y métodos para usar los compuestos.
CR20170496A 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas CR20170496A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015078507 2015-05-08
CN2016078785 2016-04-08
PCT/EP2016/059961 WO2016180695A1 (en) 2015-05-08 2016-05-04 Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection

Publications (1)

Publication Number Publication Date
CR20170496A true CR20170496A (es) 2017-12-05

Family

ID=55910966

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20170496A CR20170496A (es) 2015-05-08 2016-05-04 Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas

Country Status (33)

Country Link
US (3) US9708325B2 (es)
EP (1) EP3294740B1 (es)
JP (1) JP6738352B2 (es)
KR (1) KR20180003612A (es)
CN (1) CN107580596B (es)
AR (1) AR104528A1 (es)
AU (3) AU2016260683B2 (es)
BR (1) BR112017023959B1 (es)
CA (1) CA2982704C (es)
CL (1) CL2017002745A1 (es)
CO (1) CO2017009994A2 (es)
CR (1) CR20170496A (es)
DK (1) DK3294740T3 (es)
ES (1) ES2753777T3 (es)
HK (1) HK1247925A1 (es)
HR (1) HRP20191942T1 (es)
HU (1) HUE045906T2 (es)
IL (2) IL254947B (es)
LT (1) LT3294740T (es)
MX (2) MX2020010949A (es)
MY (1) MY182353A (es)
NZ (1) NZ735648A (es)
PE (1) PE20171620A1 (es)
PH (1) PH12017502009A1 (es)
PL (1) PL3294740T3 (es)
PT (1) PT3294740T (es)
RS (1) RS59435B1 (es)
RU (1) RU2745269C2 (es)
SG (1) SG10202108841YA (es)
SI (1) SI3294740T1 (es)
TW (2) TWI768467B (es)
UA (1) UA120450C2 (es)
WO (1) WO2016180695A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3294740B1 (en) * 2015-05-08 2019-09-04 H. Hoffnabb-La Roche Ag Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
UA124270C2 (uk) * 2016-08-29 2021-08-18 Ф. Хоффманн-Ля Рош Аг 7-заміщені сульфонімідоїлпуринони для лікування і профілактики вірусної інфекції
ES2894605T3 (es) * 2016-09-13 2022-02-15 Hoffmann La Roche Tratamiento combinado con un agonista de TLR7 y un inhibidor del ensamblaje de la cápside del VHB
JP7328977B2 (ja) 2018-02-12 2023-08-17 エフ． ホフマン－ラ ロシュ アーゲー ウイルス感染の処置および予防のための新規のスルホン化合物および誘導体
WO2019166432A1 (en) * 2018-02-28 2019-09-06 F. Hoffmann-La Roche Ag 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
CN111072667A (zh) * 2018-10-22 2020-04-28 罗欣药业(上海)有限公司 五元或六元杂环并嘧啶类化合物及其用途
SG11202108254YA (en) * 2019-02-12 2021-08-30 Ambrx Inc Compositions containing, methods and uses of antibody-tlr agonist conjugates
US20220372026A1 (en) 2019-09-20 2022-11-24 Syngenta Crop Protection Ag Pesticidally active heterocyclic derivatives with sulfur and sulfoximine containing substituents
WO2024013205A1 (en) 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Phosphorylpurinone compounds for the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4189048B2 (ja) 1997-12-26 2008-12-03 大日本住友製薬株式会社 複素環化合物
KR20080006004A (ko) * 2005-05-04 2008-01-15 화이자 리미티드 암 및 ｃ형 간염과 같은 바이러스 감염의 치료를 위한톨-유사 수용체 조절제인 2-아미도-6-아미노-8-옥소퓨린유도체
CN101239980B (zh) 2008-02-18 2011-06-22 靳广毅 免疫受体调节剂偶联体前体和偶联体及其应用
KR101687841B1 (ko) 2008-12-09 2016-12-19 길리애드 사이언시즈, 인코포레이티드 톨-유사 수용체의 조절제
US20110150836A1 (en) 2009-12-22 2011-06-23 Gilead Sciences, Inc. Methods of treating hbv and hcv infection
TWI555737B (zh) * 2011-05-24 2016-11-01 拜耳知識產權公司 含有硫醯亞胺基團之４－芳基－ｎ－苯基－１，３，５－三氮雜苯－２－胺
SI2776439T1 (sl) 2011-11-09 2018-11-30 Janssen Sciences Ireland Uc Derivati purina za zdravljenje virusnih okužb
SG11201508078XA (en) 2013-03-29 2015-11-27 Janssen Sciences Ireland Uc Macrocyclic deaza-purinones for the treatment of viral infections
DK3190113T3 (da) 2014-08-15 2021-06-07 Chia Tai Tianqing Pharmaceutical Group Co Ltd Pyrrolopyrimidinforbindelser anvendt som tlr7-agonist
EP3294740B1 (en) * 2015-05-08 2019-09-04 H. Hoffnabb-La Roche Ag Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
UA124270C2 (uk) * 2016-08-29 2021-08-18 Ф. Хоффманн-Ля Рош Аг 7-заміщені сульфонімідоїлпуринони для лікування і профілактики вірусної інфекції

Also Published As

Publication number Publication date
HUE045906T2 (hu) 2020-01-28
PL3294740T3 (pl) 2020-03-31
CN107580596B (zh) 2020-07-14
CL2017002745A1 (es) 2018-05-18
RU2017142577A3 (es) 2019-10-31
RU2017142577A (ru) 2019-06-10
UA120450C2 (uk) 2019-12-10
IL280769A (en) 2021-04-29
LT3294740T (lt) 2019-11-25
BR112017023959A2 (pt) 2018-07-17
CA2982704A1 (en) 2016-11-17
AU2016260683B2 (en) 2020-10-29
RU2745269C2 (ru) 2021-03-22
TW202108584A (zh) 2021-03-01
WO2016180695A1 (en) 2016-11-17
DK3294740T3 (da) 2019-11-04
AU2016260683A1 (en) 2017-10-12
CA2982704C (en) 2023-10-24
MX2017014033A (es) 2018-03-01
PH12017502009A1 (en) 2018-03-26
IL280769B2 (en) 2023-07-01
IL254947A0 (en) 2017-12-31
HK1247925A1 (zh) 2018-10-05
AU2020256348A1 (en) 2020-11-12
PE20171620A1 (es) 2017-11-02
IL280769B1 (en) 2023-03-01
KR20180003612A (ko) 2018-01-09
US20200109144A1 (en) 2020-04-09
BR112017023959B1 (pt) 2023-05-02
CO2017009994A2 (es) 2018-02-20
MX2020010949A (es) 2022-06-16
US20170275286A1 (en) 2017-09-28
US10399983B2 (en) 2019-09-03
IL254947B (en) 2021-02-28
MY182353A (en) 2021-01-20
SI3294740T1 (sl) 2019-12-31
TWI768467B (zh) 2022-06-21
EP3294740A1 (en) 2018-03-21
JP6738352B2 (ja) 2020-08-12
EP3294740B1 (en) 2019-09-04
AR104528A1 (es) 2017-07-26
CN107580596A (zh) 2018-01-12
TWI706954B (zh) 2020-10-11
RS59435B1 (sr) 2019-11-29
AU2020256348B2 (en) 2022-06-16
TW201716410A (zh) 2017-05-16
HRP20191942T1 (hr) 2020-01-10
ES2753777T3 (es) 2020-04-14
JP2018515509A (ja) 2018-06-14
SG10202108841YA (en) 2021-09-29
US11242345B2 (en) 2022-02-08
US20160326177A1 (en) 2016-11-10
PT3294740T (pt) 2019-10-29
AU2022204666A1 (en) 2022-07-21
NZ735648A (en) 2023-06-30
US9708325B2 (en) 2017-07-18

Similar Documents

Publication Publication Date Title
CR20170237A (es) Nuevos compuestos de 5-amino-6h-tiazolo[4,5-d]pirimidin-2,7-diona 3-sustituidos para el tratamiento y profilaxis de infecciones virales.
CO2019000932A2 (es) Nuevos compuestos sulfonimidoilpurinona 7-sustituidos y derivados para el tratamiento y la profilaxis de la infección vírica.
CO2017009994A2 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
CO2017007355A2 (es) Compuestos derivados de pirazincarbozamida y de pirazincarboxilato para el tratamiento de la infección por el virus de hepatitis b
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
UY36122A (es) ?derivados de pirrolidina-2,5-diona, composiciones farmacéuticas y métodos para usar como inhibidores ido1?
CO2017013709A2 (es) Lactamas bicíclicas.
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
UY37900A (es) Nuevos derivados de rapamicina
DOP2017000278A (es) Piridinas sustituidas y método de uso
UY35898A (es) ?compuestos inhibidores de syk y composiciones que los comprenden?.
CR20140548A (es) Derivados de aril-sultamo como moduladores de rorc
UY35630A (es) Carboxamidas primarias como inhibidores de btk
DOP2019000140A (es) Compuestos de heterociclo tetracíclicos útiles como inhibidores de la integrasa del vih
CO2019001181A2 (es) Compuestos de heteroarilcarboxamida como inhibidores de ripk2
GT201400167A (es) Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2
UY36677A (es) Compuestos tricíclicos como agentes antineoplásicos
UY35551A (es) Derivados heteroarilos como inhibidores de aldosterona sintasa
CO2018004213A2 (es) Compuesto piranodipiridínico
CO2020010306A2 (es) Compuestos de sulfonimidoilpurinona 7-sustituida y derivados para el tratamiento y profilaxis de cáncer de hígado.
CO2017009989A2 (es) Piridopirimidinonas y utilización de las mismas como moduladores de receptores de nmda
EA201990238A1 (ru) ФОСФОРСОДЕРЖАЩИЕ ПРОЛЕКАРСТВА СТИМУЛЯТОРОВ sGC
GT201600232A (es) Derivados de diheterociclo enlazado a cicloalquilo